Sugi Predict

Sugi Predict / Compounds / SCHEMBL2660944

SCHEMBL2660944

SCHEMBL2660944

CC(C)(C)c1ccc(C(Cc2ccc(NC(=O)CCC(=O)O)cc2)C(=O)N(c2ccccc2)c2ccc3cccc-3o2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GCGR P47871 12/20 0.51
▸ ADCY6 O43306 7/20 0.51
▸ ADCY3 O60266 7/20 0.51
▸ ADCY9 O60503 7/20 0.51
▸ ADCY5 O95622 7/20 0.51
▸ ADCY8 P40145 7/20 0.51
▸ ADCY7 P51828 7/20 0.51
▸ ADCY2 Q08462 7/20 0.51
▸ ADCY1 Q08828 7/20 0.51
▸ ADCY4 Q8NFM4 7/20 0.51
▸ TRPV1 Q8NER1 1/20 0.40
▸ NR1H4 Q96RI1 1/20 0.38
▸ MME P08473 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ PKM P14618 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ F9 P00740 1/20 0.37
▸ ERCC5 P28715 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2659781 0.90 GCGR (0.45) GCGRADCY6ADCY3ADCY9ADCY5
SCHEMBL11969706 0.88 GCGR (0.43) GCGRADCY6ADCY3ADCY9ADCY5
SCHEMBL2657756 0.85 PTGES (0.46) GCGRADCY6ADCY3ADCY9ADCY5
SCHEMBL2660806 0.79 GCGR (0.49) GCGRADCY6ADCY3ADCY9ADCY5
SCHEMBL2660940 0.76 GCGR (0.80) GCGRADCY6ADCY3ADCY9ADCY5
SCHEMBL2657580 0.73 ALDH1A1 (0.40) KDM4EALDH1A1HPGDHSD17B10
SCHEMBL2658204 0.73 PTGES (0.39) GCGRADCY6ADCY3ADCY9ADCY5
SCHEMBL2658725 0.72 GCGR (0.51) GCGRADCY6ADCY3ADCY9ADCY5
SCHEMBL2657011 0.71 ACKR3 (0.38) GCGRADCY6ADCY3ADCY9ADCY5
SCHEMBL11969726 0.70 GCGR (0.37) GCGRKDM4EALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10807946-B2 Antagonists of the glucagon receptor METABASIS THERAPEUTICS, INC. (US) 2020-10-20 — — US disclosed
US-20190218176-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR CITIBANK, N.A., AS ADMINISTRATIVE AGENT 2019-07-18 — — US disclosed
US-10239829-B2 Antagonists of the glucagon receptor METABASIS THERAPEUTICS, INC. (US) 2019-03-26 — — US disclosed
EP-2786985-B1 Antagonists of the glucagon receptor METABASIS THERAPEUTICS INC (US) 2018-11-28 — — EP disclosed
US-20170275246-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR METABASIS THERAPEUTICS, INC. 2017-09-28 — — US disclosed
US-9701626-B2 Antagonists of the glucagon receptor METABASIS THERAPEUTICS, INC. (US) 2017-07-11 — — US disclosed
US-20170143673-A1 Methods For Treating Heart Failure Using Glucagon Receptor Antagonists REMD Biotherapeutics, Inc 2017-05-25 — — US disclosed
US-20160009639-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR METABASIS THERAPEUTICS INC (US) 2016-01-14 — — US disclosed
US-9169201-B2 Antagonists of the glucagon receptor METABASIS THERAPEUTICS, INC. (US) 2015-10-27 — — US disclosed
EP-2786985-A2 Antagonists of the glucagon receptor Metabasis Therapeutics, Inc. (US) 2014-10-08 — — EP disclosed
EP-2129654-B1 ANTAGONISTS OF THE GLUCAGON RECEPTOR METABASIS THERAPEUTICS INC (US) 2014-05-28 — — EP disclosed
US-20140135400-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR METABASIS THERAPEUTICS, INC. (US) 2014-05-15 — — US disclosed
US-8710236-B2 Antagonists of the glucagon receptor METABASIS THERAPEUTICS, INC. (US) 2014-04-29 — — US disclosed
US-20120214769-A1 Novel Antagonists of the Glucagon Receptor METABASIS THERAPEUTICS, INC. (US) 2012-08-23 — — US disclosed
EP-2129654-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR Metabasis Therapeutics, Inc. (US) 2009-12-09 — — EP disclosed
WO-2008098244-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR METABASIS THERAPEUTICS, INC. (US) 2008-08-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160009639-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR GLP1R, GCGR, GPR119 GCGR 2/4885ADCY6 576/4885ADCY3 338/4885
US-20190218176-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR GLP1R, GCGR, GPR119 GCGR 2/4885ADCY6 563/4885ADCY3 335/4885
US-10239829-B2 Antagonists of the glucagon receptor GLP1R, GCGR, GPR119 GCGR 2/4885ADCY6 723/4885ADCY3 398/4885
US-20140135400-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR GLP1R, GCGR, GPR119 GCGR 2/4885ADCY6 576/4885ADCY3 338/4885
US-20120214769-A1 Novel Antagonists of the Glucagon Receptor GLP1R, GCGR, GPR119 GCGR 2/4885ADCY6 576/4885ADCY3 338/4885
US-20170143673-A1 Methods For Treating Heart Failure Using Glucagon Receptor Antagonists GLP1R, GCGR, GIPR GCGR 2/4885ADCY6 555/4885ADCY3 357/4885
US-20170275246-A1 NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR GLP1R, GCGR, GPR119 GCGR 2/4885ADCY6 576/4885ADCY3 338/4885
US-10807946-B2 Antagonists of the glucagon receptor GLP1R, GCGR, GPR119 GCGR 2/4885ADCY6 703/4885ADCY3 395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.